Free Trial

Guardant Health (GH) Stock Forecast & Price Target

$30.75
-0.40 (-1.28%)
(As of 07/19/2024 08:55 PM ET)

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 15 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a hold rating, and 14 have given a buy rating for GH.

Consensus Price Target

$37.38
21.58% Upside
High Forecast$50.00
Average Forecast$37.38
Low Forecast$27.00

According to the 15 analysts' twelve-month price targets for Guardant Health, the average price target is $37.38. The highest price target for GH is $50.00, while the lowest price target for GH is $27.00. The average price target represents a forecasted upside of 21.58% from the current price of $30.75.

TypeCurrent Forecast
7/23/23 to 7/22/24
1 Month Ago
6/23/23 to 6/22/24
3 Months Ago
4/24/23 to 4/23/24
1 Year Ago
7/23/22 to 7/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
13 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.38$36.91$40.40$56.27
Forecasted Upside21.58% Upside58.24% Upside78.02% Upside90.91% Upside
Get Guardant Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Guardant Health Stock vs. The Competition

TypeGuardant HealthMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside21.58% Upside2,980.95% Upside10.08% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/18/2024Bank of America
4 of 5 stars
 Boost TargetBuy ➝ Buy$28.00 ➝ $40.00+22.89%
7/17/2024The Goldman Sachs Group
2 of 5 stars
 Boost TargetBuy ➝ Buy$28.00 ➝ $32.00-1.33%
6/28/2024Guggenheim
3 of 5 stars
S. Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$36.00+23.92%
6/4/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$30.00 ➝ $38.00+38.13%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$32.00+17.09%
5/24/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$44.00 ➝ $44.00+79.01%
4/24/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$28.00+57.04%
2/26/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$40.00 ➝ $30.00+53.77%
2/23/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$60.00 ➝ $45.00+126.70%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
11/13/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$27.00+25.12%
11/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$55.00 ➝ $50.00+111.24%
10/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$50.00+72.35%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$34.00+23.10%
9/8/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
5/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$60.00 ➝ $55.00+129.26%
5/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+65.70%
2/24/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$60.00 ➝ $50.00+77.37%
2/24/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$70.00 ➝ $53.00+104.95%
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$36.00+34.83%
11/4/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$110.00 ➝ $83.00+84.12%
8/1/2022OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradePositive

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:40 AM ET.

GH Forecast - Frequently Asked Questions

What is Guardant Health's forecast for 2024?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $37.38, with a high forecast of $50.00 and a low forecast of $27.00.

Should I buy or sell Guardant Health stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There is currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares.

Does Guardant Health's stock price have much upside?

According to analysts, Guardant Health's stock has a predicted upside of 46.16% based on their 12-month stock forecasts.

Has Guardant Health been upgraded by Wall Street analysts recently?

Over the previous 90 days, Guardant Health's stock had 1 upgrade by analysts.

What analysts cover Guardant Health?

Guardant Health has been rated by research analysts at Bank of America, Canaccord Genuity Group, Craig Hallum, Guggenheim, Jefferies Financial Group, Stephens, and The Goldman Sachs Group in the past 90 days.

Do Wall Street analysts like Guardant Health more than its competitors?

Analysts like Guardant Health more than other "medical" companies. The consensus rating score for Guardant Health is 2.93 while the average consensus rating score for "medical" companies is 2.72. Learn more on how GH compares to other companies.


This page (NASDAQ:GH) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners